This inventor holds 51 USPTO granted patents and 17 published patent applications, plus 1 CIPO patent and 28 EPO patents, primarily in Neurological Disorders. Top assignees: Hoffmann-La Roche Inc., Roche Palo Alto LLC, Janssen Pharmaceutica Nv. Active years: 2008-2026.
Location History:
- Sunnyvale, CA (US) (2008 - 2013)
- Nutley, NJ (US) (2012 - 2013)
- Verona, NJ (US) (2012 - 2016)
- Lexington, MA (US) (2014 - 2024)
Company Filing History:
22 out of 5,020 
16 out of 322 
7 out of 2,099 
Years Active: 2008-2026
Areas of Expertise:
Title: Matthew C. Lucas: Innovator in Neurological Disorder Treatments
Introduction
Matthew C. Lucas, based in Verona, NJ, is a prolific inventor with an impressive portfolio of 41 patents. His innovative contributions primarily focus on compositions and methods for treating neurological disorders, signifying his commitment to advancing medical science.
Latest Patents
Among his latest patents, Lucas has developed significant methodologies aimed at addressing various neurological disorders. One notable invention involves compositions and methods for the treatment and prevention of ailments such as amyotrophic lateral sclerosis, frontotemporal degeneration, and Alzheimer’s disease. The invention details the use of an inhibitor of cytochrome P450 isoform 51A1, also known as lanosterol 14-alpha demethylase, which plays a crucial role in treating the underlying etiology of these disorders. This method can benefit patients with a specific mutant TDP-43 isoform linked to neurological aggregation and toxicity.
Another patent emphasizes compounds and methods useful for the treatment and prevention of neurological disorders, showing the versatility and importance of his work in potentially changing therapeutic strategies in neurology.
Career Highlights
Matthew Lucas has worked for notable companies in the pharmaceutical industry, including Hoffmann-La Roche Inc. and Roche Palo Alto LLC. His experience in these organizations has undoubtedly contributed to his expertise in developing innovative solutions for complex medical challenges.
Collaborations
Throughout his career, Lucas has enjoyed partnerships with remarkable colleagues such as Andrew William Thomas and Roland Jakob-Roetne. These collaborations reflect the importance of teamwork and diverse expertise in driving forward innovation in the field of medical research and development.
Conclusion
Matthew C. Lucas stands out as a significant contributor to the field of neurological research, with his 41 patents revealing a dedication to improving the quality of life for patients suffering from debilitating disorders. His innovations and methodologies demonstrate a forward-thinking approach to medical challenges, providing hope for new treatments in the future.